FDA

Glenmark Pharmaceuticals Inc., USA (Glenmark) has unveiled its new travoprost ophthalmic solution USP, 0.004% (ionic buffered solution), in the American market. This product is considered bioequivalent and therapeutically alike to the benchmark drug, Travatan Z ophthalmic solution USP, 0.004% by […]

Clinical-stage biotech firm Cassava Sciences, Inc., dedicated to pioneering innovative treatments for Alzheimer’s disease (AD) dementia, has disclosed that its phase 3 study, ReThink-ALZ, evaluating simufilam for mild-to-moderate AD, did not achieve its pre-set co-primary, secondary, and exploratory biomarker objectives.

BioNxt Solutions Inc, an innovator in the bioscience sector specializing in advanced drug delivery and diagnostic screening technologies, has announced an enhancement to its product pipeline. This expansion features proprietary drug delivery systems, including sublingual thin-film, transdermal patches, and enteric-coated

**Abbott, a prominent entity in global healthcare, has declared the initial patient operations utilizing its experimental balloon-expandable transcatheter aortic valve implantation (TAVI) system for managing severe, symptomatic aortic stenosis.** This investigational system is a preliminary phase towards Abbott’s envisioned software-directed

At the 2024 Society of Neuro-Oncology (SNO) Annual Meeting held in Texas, USA, J INTS BIO revealed its research findings on a cutting-edge brain tumor therapy named ‘JIN-001,’ developed jointly with MD Anderson Cancer Center. Partnered since 2021, MD Anderson,

The 17th CPHI & PMEC India, orchestrated by Informa Markets, a prominent name in organizing B2B events in India, began with insightful dialogues on crucial topics and exclusive sessions with prominent industry figures aiming to address transformative industry trends and

Royal Philips, recognized globally for its innovative health technology solutions, has announced a significant breakthrough that enhances access to radiology expertise for diagnostic imaging for a wider patient base. The recent US Food and Drug Administration (FDA) 510(k) approval grants

Roche has provided the latest update on its Phase III SKYSCRAPER-01 trial, which examines the efficacy of combining tiragolumab with Tecentriq (atezolizumab) versus Tecentriq alone in patients with PD-L1-high, locally advanced, or metastatic non-small cell lung cancer (NSCLC). The SKYSCRAPER-01

Empyrean Therapeutics, Inc., a leading biopharmaceutical enterprise, revealed the acquisition of a cutting-edge TLR-2 antagonist molecule from Eos Therapies, Inc., marking a key strategic initiative. This acquisition is poised to fast-track the creation of a groundbreaking cancer medication targeting challenging

ReviR Therapeutics, an innovative biotech firm specializing in creating unique small molecule RNA modulators to combat neurogenetic disorders, has received a pivotal research grant from the Kennedy’s Disease Association (KDA). This collaboration focuses on pioneering a treatment for spinal and